TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that at adjourned special general meeting of shareholders held on August 26, 2025, its shareholders voted on and approved, among others, the proposed merger with AutoMax Motors Ltd. ("AutoMax"), a leading parallel vehicle importer in Israel. T ...

Core Insights - Sai Life Sciences Limited has completed Phase II of its new Production Block (PB-11) at its API manufacturing facility in Bidar, India, enhancing its production capabilities [1][2]. Expansion Details - Phase I of PB-11, inaugurated in December 2024, had a capacity of 110 KL, and with the addition of Phase II (~91 KL), the total capacity of PB-11 now stands at approximately 200 KL, making it the largest reactor volume block at the Bidar site [2]. - The total installed reactor capacity at the Bidar facility has increased to around 700 KL following this expansion [2][7]. Strategic Importance - The CEO of Sai Life Sciences emphasized that this expansion is not just about increasing capacity but also about providing clients with the confidence to scale operations, ensuring reliable delivery, and adapting to the complexity of their programs [3]. - The PB-11 block is designed for large-scale commercial products, reinforcing the company's commitment to high-quality API and intermediate manufacturing for regulated markets such as the US, EU, and Japan [3]. Regulatory Compliance - The Bidar facility has been inspected and approved by major global regulatory agencies, including the USFDA, PMDA (Japan), and CDSCO (India), demonstrating the company's commitment to quality and compliance [3]. - Over the past three years, Sai Life Sciences has successfully undergone more than 75 customer audits, reflecting its dedication to safety and quality standards [3]. Company Overview - Sai Life Sciences is a leading integrated CRDMO, collaborating with over 300 global pharma and biotech companies to accelerate the development of new chemical entities (NCE) [4]. - The company has a workforce of over 3,400 employees across its facilities in India, the UK, and the USA [4].

What happenedAccording to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling all 12,036 shares in Q2 2025. The estimated transaction value, based on the average price for the quarter ended June 30, 2025, was approximately $9.94 million. What else to knowThe following are the fund's top holdings post-filing at the end of the second quarter:Strategy (previously MicroStrategy): ...

GSK won UK approval for its oral antibiotic treatment for uncomplicated urinary tract infections, which the medicines regulator said affect around half of women in the country https://t.co/Ibi6ZjYynp ...

Core Insights - Idorsia Ltd has introduced TRYVIO™ (aprocitentan), the first hypertension therapy targeting the endothelin pathway, addressing the need for novel treatments in difficult-to-control hypertension [1][2][3] - TRYVIO is the only endothelin receptor antagonist included in the ACC/AHA clinical practice guidelines, highlighting its significance in hypertension management [2][9] Company Overview - Idorsia aims to challenge medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [19][21] - The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol IDIA [21] Product Details - TRYVIO is a once-daily, orally active dual endothelin receptor antagonist approved in the US for systemic hypertension treatment in combination with other antihypertensives since October 2024 [11] - The drug targets a significant patient population, with approximately 26 million patients in the US potentially eligible for treatment under TRYVIO's indication [3][4] Market Opportunity - The hypertension market presents a substantial opportunity, particularly for patients with difficult-to-control hypertension, which is defined as elevated blood pressure despite the use of multiple antihypertensive drug classes [5][6] - Nearly half of US adults, around 120 million people, have hypertension, with 40 million currently treated with antihypertensive drugs [3] Clinical Insights - Patients with difficult-to-control hypertension face higher risks of cardiovascular events and premature mortality, emphasizing the need for effective treatment options [5] - Idorsia will present scientific findings at the AHA Hypertension Scientific Sessions, showcasing the efficacy of aprocitentan in achieving rapid blood pressure control and reducing urinary albumin-to-creatinine ratio (UACR) [7] Recognition - TRYVIO has been nominated for the 2025 Prix Galien USA Awards in the "Best Pharmaceutical Product" category, reflecting its innovative approach in the pharmaceutical landscape [8]

Telix Pharmaceuticals (TLX) Update / Briefing August 27, 2025 08:30 PM ET Company ParticipantsChristian Behrenbruch - MD, Group CEO & DirectorNick Lorusso - VP - Biotech Equity ResearchDavid Stanton - Head of Healthcare Equity Research, AustraliaDavid Dai - DirectorConference Call ParticipantsRobert Burns - MD & Senior Healthcare AnalystDennis Hulme - Biotech AnalystAndrew Paine - Research Analyst - HealthcareDavid Bailey - Equity Research AnalystAndy Hsieh - Research Analyst, HealthcareJohn Hester - Senior ...

Jazz Pharmaceuticals (JAZZ) Update / Briefing August 27, 2025 04:30 PM ET Company ParticipantsJack Spinks - Executive Director - IRRenee Gala - President, CEO & DirectorJoshua Allen - CTO & Chief Scientific OfficerTimothy Cloughesy - Director - Neuro-OncologyRobert Iannone - EVP, Chief Medical Officer & Global Head - R&DSamantha Pearce - EVP & Chief Commercial OfficerAnnabel Samimy - Managing DirectorBasma Radwan - Vice PresidentPoorna Kannan - Biotech Equity Research AssociateArsalan Kamran - Biotech Equit ...

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court. SO WHAT: If you purchased Spectrum Pharmaceuticals common stock during the Class Period you may be entitled to compensation ...

Company Overview - Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York, focused on discovering and developing botanical drugs for inflammatory diseases [5] - The company's lead candidate, Phyto-N, is a botanical extract with proven anti-inflammatory properties, validated in animal models for six inflammatory diseases, primarily targeting moderate to severe ulcerative colitis [5][6] Initial Public Offering (IPO) Details - Curanex announced the closing of its IPO, offering 3,750,000 shares of common stock at a price of $4.00 per share, resulting in gross proceeds of $15 million [1] - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on August 26, 2025 [1] - Underwriters were granted an option to purchase up to 562,500 additional shares within 45 days from the closing of the Offering [1] Underwriters and Legal Counsel - Dominari Securities LLC served as the lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [2] - The Crone Law Group, P.C. acted as counsel to the company, while Sichenzia Ross Ference Carmel LLP served as lead counsel to the underwriters [2] Regulatory Filings - A registration statement on Form S-1 was filed with the SEC and declared effective on August 12, 2025, with the Offering made only by means of a prospectus [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 24, 2023, to May 14, 2025 [3]. - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the efficacy of BHV-7000 for bipolar disorder [3]. - It is claimed that these misrepresentations are likely to have a significant negative impact on Biohaven's business and financial condition once revealed [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 12, 2025, to potentially be appointed as lead plaintiffs [4]. - Registration will provide shareholders with portfolio monitoring software for status updates throughout the case [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].